DON’T MISS
IamExpat FairIamExpat Job BoardIamExpat Webinars
Newsletters
EXPAT INFO
CAREER
HOUSING
EDUCATION
LIFESTYLE
EXPAT SERVICES
NEWS & ARTICLES
Home
Expat Info
German news & articles
Are BioNTech opening a UK cancer vaccine centre to avoid German bureaucracy?
Never miss a thing!Sign up for our weekly newsletters with important news stories, expat events and special offers.
Keep me updated with exclusive offers from partner companies
By signing up, you agree that we may process your information in accordance with our privacy policy

Are BioNTech opening a UK cancer vaccine centre to avoid German bureaucracy?

Never miss a thing!Sign up for our weekly newsletters with important news stories, expat events and special offers.
Keep me updated with exclusive offers from partner companies
By signing up, you agree that we may process your information in accordance with our privacy policy
or
follow us for regular updates:



Related Stories

June 2025: 8 changes affecting expats in GermanyJune 2025: 8 changes affecting expats in Germany
February 2024: 14 changes affecting expats in GermanyFebruary 2024: 14 changes affecting expats in Germany
2024 in Germany: All of the changes you need to know about2024 in Germany: All of the changes you need to know about
December 2023: 9 changes affecting expats in GermanyDecember 2023: 9 changes affecting expats in Germany
July 2023: 9 changes affecting expats in GermanyJuly 2023: 9 changes affecting expats in Germany
E-prescription service to roll out across Germany from JulyE-prescription service to roll out across Germany from July
April 2023: 9 changes affecting expats in GermanyApril 2023: 9 changes affecting expats in Germany
2023 in Germany: All of the changes you need to know about2023 in Germany: All of the changes you need to know about
For expats of all colours, shapes and sizes

Explore
Expat infoCareerHousingEducationLifestyleExpat servicesNews & articles
About us
IamExpat MediaAdvertisePost a jobContact usImpressumSitemap
More IamExpat
IamExpat Job BoardIamExpat HousingIamExpat FairWebinarsNewsletters
Privacy
Terms of usePrivacy policyCookiesAvoiding scams

Never miss a thing!Sign up for expat events, news & offers, delivered once a week.
Keep me updated with exclusive offers from partner companies
By signing up, you agree that we may process your information in accordance with our privacy policy


© 2025 IamExpat Media B.V.
© 2025 IamExpat Media B.V.
Jan 25, 2023
Olivia Logan

Editor at IamExpat Media

Editor for Germany at IamExpat Media. Olivia first came to Germany in 2013 to work as an Au Pair. Since studying English Literature and German in Scotland, Freiburg and Berlin she has worked as a features journalist and news editor.Read more

BioNTech founders Uğur Şahin and Özlem Türeci have opened a research centre in the UK, where they will develop their cancer vaccine planned for 2030. Tabloid newspaper Bild has reported that the move is motivated by Germany’s bureaucracy-heavy healthcare system.

Germany’s BioNTech opens UK cancer research centre

BioNTech, the German-Turkish company famous for developing one of the world’s first coronavirus vaccines, has announced that it will open a new cancer research centre in Cambridge.

Since their success with the coronavirus mRNA-based vaccine, wife and husband founders Uğur Şahin and Özlem Türeci have set their sights on remodelling the new mRNA technology so that it can condition the immune system to attack cancer cells rather than coronavirus.

The development would have the potential to revolutionise medicine and healthcare in Germany and internationally. According to a statement on the BioNTech website, the new Cambridge hub will employ 70 “highly-skilled scientists” and aims to provide “personalised cancer therapies for up to 10.000 patients by the end of 2030”. The first cancer patient will be enrolled in the trials by the end of 2023.

Are BioNTech burdened by German healthcare bureaucracy? 

Since the Mainz scientists announced their plan, German tabloid newspaper Bild has suggested that the move may be due to more lax medical regulations in the UK following Brexit, which would allow BioNTech to develop their cancer research more quickly. Speaking to Bild, Şahin and Türeci praised how the close working relationship between public health authorities and companies allows medical research processes to develop faster in the UK. 

In the statement on the BioNTech website, Şahin pointed to the UK’s highly efficient 2021 vaccine rollout - even according to the most recent data 93,6 percent of people in the UK have been vaccinated with one dose in comparison to 76,4 percent in Germany - as proof of how “the National Health Service, academia, the regulator and the private sector work together in an exemplary way.”

During the early stages of the vaccine rollout, the UK changed its national medical regulations which allowed the national drugs regulator to temporarily authorise the safety standards of the Pfizer / BioNTech vaccine even though the licensing process was not yet over. This option was always available to all EU countries, but the European Union chose to take the more cautious path, meaning that companies, rather than taxpayers, would have been liable if something had gone wrong.

Thumb image credit: Marcus Krauss / Shutterstock.com

By Olivia Logan